U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H33N5O4.C2H6O3S
Molecular Weight 649.7594
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of NINTEDANIB ESYLATE

SMILES

CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4N=C3O)C(=O)OC)/c5ccccc5.CCS(=O)(=O)O

InChI

InChIKey=MMMVNAGRWOJNMW-FJBFXRHMSA-N
InChI=1S/C31H33N5O4.C2H6O3S/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38;1-2-6(3,4)5/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38);2H2,1H3,(H,3,4,5)/b29-28-;

HIDE SMILES / InChI

Molecular Formula C2H6O3S
Molecular Weight 110.1334
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C31H33N5O4
Molecular Weight 539.626
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2016/6-6-2016-boehringer-ingelheim-inventiva-collaborate-develop-potential-new-treatments-idiopathic-pulmonary-fibrosis.html

Nintedanib is a receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. It is the only kinase inhibitor drug approved to treat idiopathic pulmonary fibrosis. that targets multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3). Among them, FGFR, PDGFR, and VEGFR have been implicated in IPF pathogenesis. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signaling which is crucial for the proliferation, migration, and transformation of fibroblasts representing essential mechanisms of the IPF pathology.

CNS Activity

Curator's Comment:: Nintedanib (molecular weight 539 Da) does not cross the blood–brain barrier in normal rat brain (investigator’s brochure U03-1563), as is generally expected for molecules [300 Da].

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P17948|||B3FR89
Gene ID: 2321
Gene Symbol: FLT1
Target Organism: Homo sapiens (Human)
34 nM [IC50]
Target ID: P35968
Gene ID: 3791
Gene Symbol: KDR
Target Organism: Homo sapiens (Human)
21 nM [IC50]
Target ID: P35916
Gene ID: 2324
Gene Symbol: FLT4
Target Organism: Homo sapiens (Human)
13 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
OFEV

Approved Use

Indicated for the treatment of idiopathic pulmonary fibrosis (IPF)

Launch Date

1413331200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.4 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NINTEDANIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
56.2 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NINTEDANIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.7 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NINTEDANIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2.2%
NINTEDANIB plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
dose: 200 mg 1 times / day
route: oral
experiment_type: steady
dose_type:
co-adm with
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/19846979
    unhealthy, 61 years
    population: unhealthy
    age: 61 years
    sex: M+F
    food_status:
    n:
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/19846979
    DLT: Gamma-glutamyltransferase increased...
    Dose limiting toxicities:
    Gamma-glutamyltransferase increased (grade 3, 1 patient)

    data_source:
    https://pubmed.ncbi.nlm.nih.gov/19846979
    250 mg 1 times / day steady, oral
    dose: 250 mg 1 times / day
    route: oral
    experiment_type: steady
    dose_type:
    co-adm with
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/19846979
      unhealthy, 61 years
      population: unhealthy
      age: 61 years
      sex: M+F
      food_status:
      n:
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/19846979
      DLT: Gamma-glutamyltransferase increased...
      Dose limiting toxicities:
      Gamma-glutamyltransferase increased (grade 3, 1 patient)

      data_source:
      https://pubmed.ncbi.nlm.nih.gov/19846979
      150 mg 2 times / day steady, oral
      Recommended
      dose: 150 mg 2 times / day
      route: oral
      experiment_type: steady
      dose_type: Recommended
      co-adm with
        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
        unhealthy, 67 years (range: 42 - 89 years)
        population: unhealthy
        age: 67 years (range: 42 - 89 years)
        sex: M+F
        food_status:
        n:
        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
        Disc. AE: Diarrhea, Nausea...
        AEs leading to
        discontinuation/dose reduction:​
        Diarrhea (5%)
        Nausea (2%)
        Decreased appetite (2%)

        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
        150 mg 2 times / day steady, oral
        Recommended
        dose: 150 mg 2 times / day
        route: oral
        experiment_type: steady
        dose_type: Recommended
        co-adm with
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000CrossR.pdf
          unhealthy, 67 years (range: 42 - 89 years)
          population: unhealthy
          age: 67 years (range: 42 - 89 years)
          sex: M+F
          food_status:
          n:
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000CrossR.pdf
          Disc. AE: Weight decreased, Alanine aminotransferase increased...
          AEs leading to
          discontinuation/dose reduction:​
          Weight decreased (1.1%)
          Alanine aminotransferase increased (0.6%)

          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000CrossR.pdf
          150 mg 2 times / day steady, oral
          Recommended
          dose: 150 mg 2 times / day
          route: oral
          experiment_type: steady
          dose_type: Recommended
          co-adm with
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
            unhealthy, 67 years (range: 42 - 89 years)
            population: unhealthy
            age: 67 years (range: 42 - 89 years)
            sex: M+F
            food_status:
            n:
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
            Disc. AE: Vomiting, Abdominal pain...
            AEs leading to
            discontinuation/dose reduction:​
            Vomiting (1%)
            Abdominal pain (1%)
            Asthenia (0.7%)
            Hepatic enzyme increased (0.6%)
            Aspartate aminotransferase increased (0.4%)
            Blood bilirubin increased (0.4%)

            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
            150 mg 2 times / day steady, oral
            Recommended
            dose: 150 mg 2 times / day
            route: oral
            experiment_type: steady
            dose_type: Recommended
            co-adm with
              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
              unhealthy, 67 years (range: 42 - 89 years)
              population: unhealthy
              age: 67 years (range: 42 - 89 years)
              sex: M+F
              food_status:
              n:
              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
              Disc. AE: Diarrhea, Nausea...
              AEs leading to
              discontinuation/dose reduction:​
              Diarrhea (10.9%)
              Nausea (2.1%)
              Decreased appetite (0.8%)
              Weight decreased (0.6%)
              Abdominal pain (0.8%)
              Abdominal pain upper (0.8%)
              Transaminases increased (0.4%)
              Hepatic function abnormal (0.7%)

              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
              250 mg 2 times / day steady, oral
              MTD
              dose: 250 mg 2 times / day
              route: oral
              experiment_type: steady
              dose_type: MTD
              co-adm with
                data_source:
                https://pubmed.ncbi.nlm.nih.gov/25795637
                unhealthy, adult
                population: unhealthy
                age: adult
                sex:
                food_status:
                n:
                data_source:
                https://pubmed.ncbi.nlm.nih.gov/25795637
                DLT: Elevated liver enzymes...
                Dose limiting toxicities:
                Elevated liver enzymes (grade 3, 2 patients)

                data_source:
                https://pubmed.ncbi.nlm.nih.gov/25795637
                600 mg 1 times / day multiple, oral
                Overdose
                dose: 600 mg 1 times / day
                route: oral
                experiment_type: multiple
                dose_type: Overdose
                co-adm with
                  data_source:
                  https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
                  unhealthy, adult
                  population: unhealthy
                  age: adult
                  sex:
                  food_status:
                  n:
                  data_source:
                  https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
                  Other AEs: Nasopharyngitis...
                  600 mg 2 times / day multiple, oral
                  Overdose
                  dose: 600 mg 2 times / day
                  route: oral
                  experiment_type: multiple
                  dose_type: Overdose
                  co-adm with
                    data_source:
                    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
                    unhealthy, adult
                    population: unhealthy
                    age: adult
                    sex:
                    food_status:
                    n:
                    data_source:
                    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
                    AEs

                    AEs

                    AESignificanceDosePopulation
                    Gamma-glutamyltransferase increased grade 3,1 pts%
                    DLT
                    200 mg 1 times / day steady, oral
                    dose: 200 mg 1 times / day
                    route: oral
                    experiment_type: steady
                    dose_type:
                    co-adm with
                      data_source:
                      https://pubmed.ncbi.nlm.nih.gov/19846979
                      unhealthy, 61 years
                      population:
                      age:
                      sex:
                      food_status:
                      n:
                      data_source:
                      https://pubmed.ncbi.nlm.nih.gov/19846979
                      Gamma-glutamyltransferase increased grade 3,1 pts%
                      DLT
                      250 mg 1 times / day steady, oral
                      dose: 250 mg 1 times / day
                      route: oral
                      experiment_type: steady
                      dose_type:
                      co-adm with
                        data_source:
                        https://pubmed.ncbi.nlm.nih.gov/19846979
                        unhealthy, 61 years
                        population:
                        age:
                        sex:
                        food_status:
                        n:
                        data_source:
                        https://pubmed.ncbi.nlm.nih.gov/19846979
                        Nasopharyngitis
                        600 mg 1 times / day multiple, oral
                        Overdose
                        dose: 600 mg 1 times / day
                        route: oral
                        experiment_type: multiple
                        dose_type: Overdose
                        co-adm with
                          data_source:
                          https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
                          unhealthy, adult
                          population:
                          age:
                          sex:
                          food_status:
                          n:
                          data_source:
                          https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
                          Aspartate aminotransferase increased 0.4%
                          Disc. AE
                          150 mg 2 times / day steady, oral
                          Recommended
                          dose: 150 mg 2 times / day
                          route: oral
                          experiment_type: steady
                          dose_type: Recommended
                          co-adm with
                            data_source:
                            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                            unhealthy, 67 years (range: 42 - 89 years)
                            Blood bilirubin increased 0.4%
                            Disc. AE
                            150 mg 2 times / day steady, oral
                            Recommended
                            dose: 150 mg 2 times / day
                            route: oral
                            experiment_type: steady
                            dose_type: Recommended
                            co-adm with
                              data_source:
                              https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                              unhealthy, 67 years (range: 42 - 89 years)
                              Transaminases increased 0.4%
                              Disc. AE
                              150 mg 2 times / day steady, oral
                              Recommended
                              dose: 150 mg 2 times / day
                              route: oral
                              experiment_type: steady
                              dose_type: Recommended
                              co-adm with
                                data_source:
                                https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                                unhealthy, 67 years (range: 42 - 89 years)
                                Alanine aminotransferase increased 0.6%
                                Disc. AE
                                150 mg 2 times / day steady, oral
                                Recommended
                                dose: 150 mg 2 times / day
                                route: oral
                                experiment_type: steady
                                dose_type: Recommended
                                co-adm with
                                  data_source:
                                  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000CrossR.pdf
                                  unhealthy, 67 years (range: 42 - 89 years)
                                  Hepatic enzyme increased 0.6%
                                  Disc. AE
                                  150 mg 2 times / day steady, oral
                                  Recommended
                                  dose: 150 mg 2 times / day
                                  route: oral
                                  experiment_type: steady
                                  dose_type: Recommended
                                  co-adm with
                                    data_source:
                                    https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                                    unhealthy, 67 years (range: 42 - 89 years)
                                    Weight decreased 0.6%
                                    Disc. AE
                                    150 mg 2 times / day steady, oral
                                    Recommended
                                    dose: 150 mg 2 times / day
                                    route: oral
                                    experiment_type: steady
                                    dose_type: Recommended
                                    co-adm with
                                      data_source:
                                      https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                                      unhealthy, 67 years (range: 42 - 89 years)
                                      Asthenia 0.7%
                                      Disc. AE
                                      150 mg 2 times / day steady, oral
                                      Recommended
                                      dose: 150 mg 2 times / day
                                      route: oral
                                      experiment_type: steady
                                      dose_type: Recommended
                                      co-adm with
                                        data_source:
                                        https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                                        unhealthy, 67 years (range: 42 - 89 years)
                                        Hepatic function abnormal 0.7%
                                        Disc. AE
                                        150 mg 2 times / day steady, oral
                                        Recommended
                                        dose: 150 mg 2 times / day
                                        route: oral
                                        experiment_type: steady
                                        dose_type: Recommended
                                        co-adm with
                                          data_source:
                                          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                                          unhealthy, 67 years (range: 42 - 89 years)
                                          Abdominal pain upper 0.8%
                                          Disc. AE
                                          150 mg 2 times / day steady, oral
                                          Recommended
                                          dose: 150 mg 2 times / day
                                          route: oral
                                          experiment_type: steady
                                          dose_type: Recommended
                                          co-adm with
                                            data_source:
                                            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                                            unhealthy, 67 years (range: 42 - 89 years)
                                            Abdominal pain 0.8%
                                            Disc. AE
                                            150 mg 2 times / day steady, oral
                                            Recommended
                                            dose: 150 mg 2 times / day
                                            route: oral
                                            experiment_type: steady
                                            dose_type: Recommended
                                            co-adm with
                                              data_source:
                                              https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                                              unhealthy, 67 years (range: 42 - 89 years)
                                              Decreased appetite 0.8%
                                              Disc. AE
                                              150 mg 2 times / day steady, oral
                                              Recommended
                                              dose: 150 mg 2 times / day
                                              route: oral
                                              experiment_type: steady
                                              dose_type: Recommended
                                              co-adm with
                                                data_source:
                                                https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                                                unhealthy, 67 years (range: 42 - 89 years)
                                                Abdominal pain 1%
                                                Disc. AE
                                                150 mg 2 times / day steady, oral
                                                Recommended
                                                dose: 150 mg 2 times / day
                                                route: oral
                                                experiment_type: steady
                                                dose_type: Recommended
                                                co-adm with
                                                  data_source:
                                                  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                                                  unhealthy, 67 years (range: 42 - 89 years)
                                                  Vomiting 1%
                                                  Disc. AE
                                                  150 mg 2 times / day steady, oral
                                                  Recommended
                                                  dose: 150 mg 2 times / day
                                                  route: oral
                                                  experiment_type: steady
                                                  dose_type: Recommended
                                                  co-adm with
                                                    data_source:
                                                    https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                                                    unhealthy, 67 years (range: 42 - 89 years)
                                                    Weight decreased 1.1%
                                                    Disc. AE
                                                    150 mg 2 times / day steady, oral
                                                    Recommended
                                                    dose: 150 mg 2 times / day
                                                    route: oral
                                                    experiment_type: steady
                                                    dose_type: Recommended
                                                    co-adm with
                                                      data_source:
                                                      https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000CrossR.pdf
                                                      unhealthy, 67 years (range: 42 - 89 years)
                                                      Diarrhea 10.9%
                                                      Disc. AE
                                                      150 mg 2 times / day steady, oral
                                                      Recommended
                                                      dose: 150 mg 2 times / day
                                                      route: oral
                                                      experiment_type: steady
                                                      dose_type: Recommended
                                                      co-adm with
                                                        data_source:
                                                        https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                                                        unhealthy, 67 years (range: 42 - 89 years)
                                                        Decreased appetite 2%
                                                        Disc. AE
                                                        150 mg 2 times / day steady, oral
                                                        Recommended
                                                        dose: 150 mg 2 times / day
                                                        route: oral
                                                        experiment_type: steady
                                                        dose_type: Recommended
                                                        co-adm with
                                                          data_source:
                                                          https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
                                                          unhealthy, 67 years (range: 42 - 89 years)
                                                          population:
                                                          age:
                                                          sex:
                                                          food_status:
                                                          n:
                                                          data_source:
                                                          https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
                                                          Nausea 2%
                                                          Disc. AE
                                                          150 mg 2 times / day steady, oral
                                                          Recommended
                                                          dose: 150 mg 2 times / day
                                                          route: oral
                                                          experiment_type: steady
                                                          dose_type: Recommended
                                                          co-adm with
                                                            data_source:
                                                            https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
                                                            unhealthy, 67 years (range: 42 - 89 years)
                                                            population:
                                                            age:
                                                            sex:
                                                            food_status:
                                                            n:
                                                            data_source:
                                                            https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
                                                            Nausea 2.1%
                                                            Disc. AE
                                                            150 mg 2 times / day steady, oral
                                                            Recommended
                                                            dose: 150 mg 2 times / day
                                                            route: oral
                                                            experiment_type: steady
                                                            dose_type: Recommended
                                                            co-adm with
                                                              data_source:
                                                              https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf
                                                              unhealthy, 67 years (range: 42 - 89 years)
                                                              Diarrhea 5%
                                                              Disc. AE
                                                              150 mg 2 times / day steady, oral
                                                              Recommended
                                                              dose: 150 mg 2 times / day
                                                              route: oral
                                                              experiment_type: steady
                                                              dose_type: Recommended
                                                              co-adm with
                                                                data_source:
                                                                https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
                                                                unhealthy, 67 years (range: 42 - 89 years)
                                                                population:
                                                                age:
                                                                sex:
                                                                food_status:
                                                                n:
                                                                data_source:
                                                                https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf
                                                                Elevated liver enzymes grade 3,2 pts%
                                                                DLT
                                                                250 mg 2 times / day steady, oral
                                                                MTD
                                                                dose: 250 mg 2 times / day
                                                                route: oral
                                                                experiment_type: steady
                                                                dose_type: MTD
                                                                co-adm with
                                                                  data_source:
                                                                  https://pubmed.ncbi.nlm.nih.gov/25795637
                                                                  unhealthy, adult
                                                                  population:
                                                                  age:
                                                                  sex:
                                                                  food_status:
                                                                  n:
                                                                  data_source:
                                                                  https://pubmed.ncbi.nlm.nih.gov/25795637
                                                                  OverviewDrug as perpetrator​

                                                                  Drug as perpetrator​

                                                                  TargetModalityActivityMetaboliteClinical evidence
                                                                  no [IC50 16 uM]
                                                                  no [IC50 24.5 uM]
                                                                  no [IC50 24.5 uM]
                                                                  no [IC50 70.1 uM]
                                                                  no [IC50 77.6 uM]
                                                                  no [IC50 85.5 uM]
                                                                  no [IC50 >200 uM]
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  weak
                                                                  weak
                                                                  weak
                                                                  weak
                                                                  yes [IC50 0.88 uM]
                                                                  Drug as victim

                                                                  Drug as victim

                                                                  TargetModalityActivityMetaboliteClinical evidence
                                                                  major
                                                                  minor
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  no
                                                                  yes
                                                                  yes
                                                                  yes
                                                                  yes
                                                                  yes
                                                                  yes
                                                                  yes
                                                                  yes
                                                                  yes (co-administration study)
                                                                  Comment: Coadministration with the P-gp and CYP3A4 inhibitor ketoconazole increased exposure of nintedanib by 1.61-fold based on AUC and 1.83-fold based on Cmax.
                                                                  Page: 9
                                                                  Tox targets

                                                                  Tox targets

                                                                  PubMed

                                                                  PubMed

                                                                  TitleDatePubMed
                                                                  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
                                                                  2008 Jun 15
                                                                  Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers.
                                                                  2011 Apr
                                                                  A new hope for idiopathic pulmonary fibrosis.
                                                                  2014 May 29
                                                                  Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
                                                                  2014 Sep
                                                                  Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
                                                                  2015 Jul
                                                                  Nintedanib in the treatment of idiopathic pulmonary fibrosis.
                                                                  2015 Jun
                                                                  Patents

                                                                  Sample Use Guides

                                                                  150 mg twice daily approximately 12 hours apart
                                                                  Route of Administration: Oral
                                                                  10-80 nmol/L resulted in 50% inhibition (EC50) of cell proliferation in human umbilical vascular endothelial cell HUVEC, microvascular skin endothelial cells HMSEC, umbilical artery smooth muscle cells HUASMC
                                                                  Substance Class Chemical
                                                                  Created
                                                                  by admin
                                                                  on Fri Jun 25 20:34:55 UTC 2021
                                                                  Edited
                                                                  by admin
                                                                  on Fri Jun 25 20:34:55 UTC 2021
                                                                  Record UNII
                                                                  42F62RTZ4G
                                                                  Record Status Validated (UNII)
                                                                  Record Version
                                                                  • Download
                                                                  Name Type Language
                                                                  NINTEDANIB ESYLATE
                                                                  USAN  
                                                                  USAN  
                                                                  Official Name English
                                                                  METHYL (3Z)-3-(((4-(N-METHYL-2-(4-METHYLPIPERAZIN-1-YL)ACETAMIDO)PHENYL)AMINO) (PHENYL)METHYLIDENE)-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE ETHANESULFONATE
                                                                  Systematic Name English
                                                                  NINTEDANIB ETHANESULFONATE
                                                                  Common Name English
                                                                  NINTEDANIB ESYLATE [ORANGE BOOK]
                                                                  Common Name English
                                                                  NINTEDANIB ESYLATE [USAN]
                                                                  Common Name English
                                                                  NINTEDANIB ESILATE [WHO-DD]
                                                                  Common Name English
                                                                  NINTEDANIB ETHANESULFONATE [JAN]
                                                                  Common Name English
                                                                  OFEV
                                                                  Brand Name English
                                                                  Classification Tree Code System Code
                                                                  NCI_THESAURUS C1742
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  NCI_THESAURUS C155727
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  Code System Code Type Description
                                                                  PUBCHEM
                                                                  9809714
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  PRIMARY
                                                                  EPA CompTox
                                                                  656247-18-6
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  PRIMARY
                                                                  JAPANESE REVIEW
                                                                  OFEV
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  PRIMARY APPROVED JULY 2015
                                                                  NCI_THESAURUS
                                                                  C154570
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  PRIMARY
                                                                  CAS
                                                                  656247-18-6
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  PRIMARY
                                                                  RXCUI
                                                                  1592736
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  PRIMARY RxNorm
                                                                  FDA UNII
                                                                  42F62RTZ4G
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  PRIMARY
                                                                  EVMPD
                                                                  SUB179667
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  PRIMARY
                                                                  DRUG BANK
                                                                  DBSALT001111
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  PRIMARY
                                                                  MESH
                                                                  C530716
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  PRIMARY
                                                                  ChEMBL
                                                                  CHEMBL502835
                                                                  Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
                                                                  PRIMARY
                                                                  Related Record Type Details
                                                                  PARENT -> SALT/SOLVATE
                                                                  Related Record Type Details
                                                                  ACTIVE MOIETY